Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients

Vincenza Conteduca, Orazio Caffo, Lucia Fratino, Giovanni Lo Re, Umberto Basso, Alessandro D'Angelo, Maddalena Donini, Francesco Verderame, Raffaele Ratta, Giuseppe Procopio, Enrico Campadelli, Francesco Massari, Donatello Gasparro, Paola Ermacora, Caterina Messina, Monica Giordano, Daniele Alesini, Vittorina Zagonel, Antonello Veccia, Cristian LolliFrancesca Maines, Ugo De Giorgi

Research output: Contribution to journalArticle

Abstract

Background: The objective of this study was to analyze the impact of visceral metastases in castration-resistant prostate cancer (CRPC) treated with abiraterone. Materials & methods: All CRPC patients received abiraterone 1000 mg daily plus prednisone 10 mg orally daily. Liver and lung metastases were considered as visceral metastases. Results: Of 265 CRPC patients, 49 had visceral metastases. Results on progression-free survival were not significantly different in patients with or without visceral metastases. Conversely, the median overall survival between the two groups was 12.4 and 18.5 months (p = 0.01), respectively, and median overall survival of patients with liver-only disease versus other sites was 10.5 versus 18.5 months (p = 0.006), respectively. Conclusion: Visceral disease appears to be an important predictor of clinical outcome in CRPC patients treated with abiraterone.

Original languageEnglish
Pages (from-to)2881-2891
Number of pages11
JournalFuture Oncology
Volume11
Issue number21
DOIs
Publication statusPublished - Nov 1 2015

    Fingerprint

Keywords

  • abiraterone acetate
  • castration-resistant prostate cancer
  • liver
  • survival
  • visceral metastases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Conteduca, V., Caffo, O., Fratino, L., Lo Re, G., Basso, U., D'Angelo, A., Donini, M., Verderame, F., Ratta, R., Procopio, G., Campadelli, E., Massari, F., Gasparro, D., Ermacora, P., Messina, C., Giordano, M., Alesini, D., Zagonel, V., Veccia, A., ... De Giorgi, U. (2015). Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncology, 11(21), 2881-2891. https://doi.org/10.2217/fon.15.158